DJIA 16,204.97 -211.61 -1.29%
NASDAQ 4,363.14 -146.42 -3.25%
S&P 500 1,880.05 -35.40 -1.85%
market minute promo

Gilead Sciences (NASDAQ: GILD)

85.14 -1.54 (-1.78%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GILD $85.14 -1.78%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $86.68
Previous Close $86.68
Daily Range $84.45 - $88.02
52-Week Range $81.89 - $123.37
Market Cap $122.7B
P/E Ratio 6.87
Dividend (Yield) $1.72 (2.0%)
Ex-Dividend Date
Dividend Pay Date
03/14/16
03/30/16
Volume 15,731,426
Average Daily Volume 12,716,472
Current FY EPS $12.00

Sector

Healthcare

Industry

Drug Makers

Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website: http://www.gilead.com/

News & Commentary

Is Gilead Sciences Finally Nearing a Bottom?

The biotech remains a great buy, despite its worrisome start to the new year.

Should Younger Investors Follow The Strategy Of Retirees In Allocating Capital?

Barron's: Here Comes $20 Oil

Barron's Picks And Pans: Kinder Morgan, Gilead Sciences And More

It Is A Stock Picker's Market

How Analysts Value Gilead Now After Earnings

Grading Gilead Sciences' Performance in 2015

The highs and lows (but mostly highs) from Gilead Sciences’ earnings call.

1 Company Gilead Sciences Should Consider Buying Right Now

Given that it's flush with cash but shaky on growth, an acquisition could be in Gilead Sciences future. This company stands out as the most obvious target.

Gilead Sciences 2016 Guidance: Sandbagging Wall Street Again?

The company's track record of beating forecasts could continue again this year.

Gilead's Glory Days Are Over -- Here's Why You Should Dump the Stock

See More GILD News...

GILD's Top Competitors

GILD $85.14 (-1.78%)
Current stock: GILD
AMGN $145.04 (-3.25%)
Current stock: AMGN
CELG $97.89 (-3.96%)
Current stock: CELG
$0.00 (0.00%)
Current stock: